-
Study aim
-
Determining the effect of inhaled beta2 agonist (Ventolin) in the treatment of bronchiolitis
-
Design
-
Clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 80 patients. The rand function of Excel software was used for randomization.
-
Settings and conduct
-
The study will be conducted at Shahid Beheshti Hospital in Kashan and will continue until discharge from the hospital. Finally, the patients were divided into 2 groups. Standard treatment group: supportive treatment including oxygen and serum therapy is prescribed. Intervention group B: participants in this group, in addition to supportive therapy such as oxygen supplementation and receiving serum, are treated with a salbutamol nebulizer of 0.15 mg/kilogram of body weight. The production of GSK company, which will be prepared in coordination with the hospital pharmacy, will be given once every 20 minutes for an hour and then every 4 hours along with routine treatment.
Participants, researchers, and outcome assessors were blinded in this study.
-
Participants/Inclusion and exclusion criteria
-
Entry criteria:
age less than 2 years;
Exit criteria:
who will not be hospitalized due to the low severity of the disease
Age less than 1 month or more than 2 years
Immunodeficiency
Congenital heart,lung disease
Severe and mild severity of the disease
-
Intervention groups
-
The participants in this group, in addition to supportive treatment such as oxygen supplementation and receiving serum, are treated with a salbutamol nebulizer of 0.15 mg per kilogram of body weight produced by GSK nebulizers, which will be prepared in coordination with the hospital pharmacy, first once every 20 minutes until One hour and then every 4 hours along with routine treatment
-
Main outcome variables
-
Respiratory rate, blood oxygen saturation, whizzing, retraction